NEW YORK (GenomeWeb News) – The National Cancer Institute has renewed a contract agreement with GeneArt, under which the company already has developed over 3,500 synthetic genes for around $3.5 million, the company said Friday.
GeneArt said it has agreed to develop another 200 genes for NCI’s Mammalian Gene Collection Program for an additional $1.9 million.
The contract the company initially agreed to in January 2007 was assigned by the company SAIC-Frederick on behalf of NCI and would allow it to perform up to $6.5 million in gene synthesis services for the institute.
The MGC Program is a collection of human and mouse genes to be used for basic research and for clinical R&D.
Due to a large number of repetitive DNA sequence elements and toxic elements involved in the research, GeneArt said it had to “further advance its existing technologies and establish new production techniques.”